Medifast CEO Daniel Chard Buys $178K in Stock Amidst Activist Agreement

summarizeSummary

Medifast CEO Daniel R. Chard purchased $178,725 worth of company stock on the open market, signaling executive confidence following a recent activist investor agreement and prior financial challenges.

check_boxKey Events

• CEO Open Market Purchase

  Daniel R. Chard, Chairman & CEO, purchased 17,678 shares of Medifast common stock for $178,724.58 at an average price of $10.11 per share on March 20, 2026.

• Routine Tax Withholding

  Chard also disposed of 29,808 shares valued at $287,284.45 through mandatory tax withholdings related to restricted stock unit vesting between March 13 and March 25, 2026.

• Restricted Stock Unit Grants

  The CEO received grants of 41,795 restricted stock units on March 25, 2026, which will vest over time as part of his compensation.

• Strategic Context

  This open market purchase follows a cooperation agreement with activist investor Steamboat Capital (March 20, 2026) and comes after the company reported a significant 36% revenue drop and a net loss in its 2025 annual report.

auto_awesomeAnalysis

Medifast's CEO, Daniel R. Chard, made an open market purchase of company stock, signaling confidence in the company's future. This purchase, valued at over $178,000, is particularly notable given the company's recent financial performance, which included a significant revenue drop and a net loss reported in its 2025 annual report. The buy also follows closely on the heels of a cooperation agreement with activist investor Steamboat Capital, suggesting a potential alignment or renewed strategic focus. While the CEO also had routine tax-related sales, the open market purchase by a key executive often indicates a belief that the stock is undervalued or that positive developments are ahead.